Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abacavir Sulfate

FDA-approved product (tablet, oral), marketed as Abacavir Sulfate, Ziagen.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Abacavir Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Immunodeficiency disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abacavir Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abacavir Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Preliminary Testing and Development of a Short Digital Intervention for Patients on Waiting Lists for Psychological Treatment

    NCT07499219 · start 2026-03-24

    Registered record
    Registry ID
    NCT07499219
    Conditions
    Depression; Anxiety
    Interventions
    Digital therapy program (short); Digital therapy program (long); Mental health advice
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2026-03-24
    Completion
    2034-10
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Anxiety
    InterventionDigital therapy program (short); Digital therapy program (long); Mental health advice
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Study of GS-3242 in Participants With HIV-1; Substudy-05

    NCT07001319 · start 2025-05-29

    Registered record
    Registry ID
    NCT07001319
    Conditions
    HIV-1-infection
    Interventions
    GS-3242; BVY; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-05-29
    Completion
    2026-04-16
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionGS-3242; BVY; Standard of Care
    PhasePhase 1
    Registry statusCompleted

  • A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

    NCT06337032 · start 2024-08-27

    Registered record
    Registry ID
    NCT06337032
    Conditions
    HIV-1-infection
    Interventions
    F/TAF (High Dose Tablet); F/TAF (Low Dose Tablet); F/TAF (Lowest Dose Tablet); F/TAF (High Dose TOS); F/TAF (Low Dose TOS); F/TAF (Lowest Dose TOS); E/C/F/TAF; E/C/F/TAF (Low Dose); Cobicistat (High Dose); Cobicistat (Low Dose); Cobicistat (TOS); B/F/TAF (High Dose); B/F/TAF (Low Dose); B/F/TAF (High Dose TOS); B/F/TAF (Low Dose TOS); B/F/TAF (Lowest Dose TOS); 3rd ARV Agent; Nucleos(t)ide reverse transcriptase inhibitors (NRTI); ATV; DRV; Lopinavir Boosted with ritonavir (LPV/r)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-08-27
    Completion
    2034-03
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionF/TAF (High Dose Tablet); F/TAF (Low Dose Tablet); F/TAF (Lowest Dose Tablet); F/TAF (High Dose TOS) +17 more
    PhasePhase 4
    Registry statusRecruiting

  • A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

    NCT05729568 · start 2023-05-15

    Registered record
    Registry ID
    NCT05729568
    Conditions
    HIV-1 Infection
    Interventions
    Teropavimab; Zinlirvimab; Lenacapavir Tablet; Lenacapavir Injection; Antiretroviral Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-05-15
    Completion
    2030-12
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionTeropavimab; Zinlirvimab; Lenacapavir Tablet; Lenacapavir Injection +1 more
    PhasePhase 2
    Registry statusActive not recruiting

  • All Children in Focus (ABC) 0-2 Years: A Pilot Study

    NCT06037642 · start 2023-02-01

    Registered record
    Registry ID
    NCT06037642
    Conditions
    Parent-Child Relations; Parenting
    Interventions
    ABC 0-2 years; waiting list
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-02-01
    Completion
    2023-06-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParent-Child Relations; Parenting
    InterventionABC 0-2 years; waiting list
    PhaseNot applicable
    Registry statusCompleted

  • Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

    NCT03256422 · start 2017-09-07

    Registered record
    Registry ID
    NCT03256422
    Conditions
    HIV Infections
    Interventions
    Treatment discontinuation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-07
    Completion
    2020-03-02
    Enrolment
    640

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTreatment discontinuation
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

    NCT02938520 · start 2016-10-27

    Registered record
    Registry ID
    NCT02938520
    Conditions
    HIV Infections
    Interventions
    Cabotegravir (CAB) tablet; Rilpivirine (RPV) tablet; Cabotegravir - Injectable Suspension (CAB LA); Rilpivirine - Injectable Suspension (RPV LA); ABC/DTG/3TC STR - Tablet; DTG Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2016-10-27
    Completion
    2029-12-31
    Enrolment
    631

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCabotegravir (CAB) tablet; Rilpivirine (RPV) tablet; Cabotegravir - Injectable Suspension (CAB LA); Rilpivirine - Injectable Suspension (RPV LA) +2 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

    NCT02893488 · start 2016-09-01

    Registered record
    Registry ID
    NCT02893488
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    DTG/ABC/3TC FDC DISPERSIBLE TABLET; EPZICOM (ABC/3TC); TIVICAY (DTG)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-09-01
    Completion
    2016-11-25
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    InterventionDTG/ABC/3TC FDC DISPERSIBLE TABLET; EPZICOM (ABC/3TC); TIVICAY (DTG)
    PhasePhase 1
    Registry statusCompleted

  • Dolutegravir in Reservoirs

    NCT02924389 · start 2016-09

    Registered record
    Registry ID
    NCT02924389
    Conditions
    HIV
    Interventions
    dolutegravir; Triumeq; Truvada
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2016-09
    Completion
    2019-09-11
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiondolutegravir; Triumeq; Truvada
    PhasePhase 4
    Registry statusTerminated

  • Interaction With HIV Antiretroviral Agents

    NCT02556268 · start 2016-02-23

    Registered record
    Registry ID
    NCT02556268
    Conditions
    HIV-DDI
    Interventions
    Riociguat (Adempas, BAY 63-2521); ATRIPLA; COMPLERA; STRIBILD; TRIUMEQ; Antiretroviral protease inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02-23
    Completion
    2016-12-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-DDI
    InterventionRiociguat (Adempas, BAY 63-2521); ATRIPLA; COMPLERA; STRIBILD +2 more
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients

    NCT02596334 · start 2015-12-23

    Registered record
    Registry ID
    NCT02596334
    Conditions
    HIV
    Interventions
    dolutegravir 50mg +abacavir 600mg +lamivudine 300mg; dolutegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-12-23
    Completion
    2018-06-23
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiondolutegravir 50mg +abacavir 600mg +lamivudine 300mg; dolutegravir
    PhasePhase 3
    Registry statusTerminated

  • Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

    NCT02605954 · start 2015-11-18

    Registered record
    Registry ID
    NCT02605954
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-18
    Completion
    2018-01-24
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

    NCT02539576 · start 2015-10

    Registered record
    Registry ID
    NCT02539576
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    ABC/DTG/3TC FDC tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-10
    Completion
    2015-11
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    InterventionABC/DTG/3TC FDC tablet
    PhasePhase 1
    Registry statusCompleted

  • HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

    NCT02513147 · start 2015-06

    Registered record
    Registry ID
    NCT02513147
    Conditions
    HIV-1
    Interventions
    Dolutegravir; PI; 2 NRTI; 2 NRTI
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-06
    Completion
    2016-11
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionDolutegravir; PI; 2 NRTI; 2 NRTI
    PhasePhase 4
    Registry statusCompleted

  • Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio

    NCT03178084 · start 2014-10-15

    Registered record
    Registry ID
    NCT03178084
    Conditions
    HIV/AIDS
    Interventions
    Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID; Efavirenz QD + Zidovudine/Lamivudine BID; Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-10-15
    Completion
    2017-03-07
    Enrolment
    721

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS
    InterventionMaraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID; Efavirenz QD + Zidovudine/Lamivudine BID; Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD
    PhasePhase 3
    Registry statusCompleted